Related Experiment Videos
Aberrant DNA methylation in cutaneous malignancies.
Remco van Doorn1, Nelleke A Gruis, Rein Willemze
1Department of Dermatology, Leiden University Medical Center, Albinusdreef 2, 2333 AL Leiden, The Netherlands.
Seminars in Oncology
|October 8, 2005
Summary
Epigenetic alterations, particularly DNA methylation changes, are key drivers in skin cancer development. Understanding these epigenetic shifts in basal cell carcinoma, squamous cell carcinoma, melanoma, and lymphoma offers potential therapeutic targets.
Area of Science:
- Oncology
- Epigenetics
- Dermatology
Background:
- Genetic mutations and epigenetic alterations are crucial in cancer development.
- Aberrant DNA methylation of tumor-suppressor genes leads to transcriptional silencing and cancer progression.
- Skin cancers, including basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (SCC), melanoma, and cutaneous lymphoma, are the most common human malignancies.
Purpose of the Study:
- To review current knowledge on DNA methylation alterations in major skin cancers.
- To discuss the role of ultraviolet radiation in the epigenetics of skin tumorigenesis.
- To highlight the potential of targeting epigenetic modifications for skin cancer treatment.
Main Methods:
- Review of existing literature on DNA methylation in BCC, SCC, melanoma, and cutaneous lymphoma.
- Analysis of studies investigating the "epigenotoxic" effects of ultraviolet radiation.
- Synthesis of findings on promoter hypermethylation and its impact on tumor-suppressor genes.
Main Results:
- Aberrant DNA methylation is a significant factor in the pathogenesis of skin cancers.
- Numerous potential tumor-suppressor genes are epigenetically silenced in skin malignancies.
- Ultraviolet radiation may induce "epigenotoxic" changes contributing to skin cancer.
Conclusions:
- Epigenetic silencing of tumor-suppressor genes is a critical event in skin cancer.
- Further research into DNA methylation patterns can identify novel therapeutic strategies.
- Targeting epigenetic modifications, such as with demethylating agents, shows promise for treating skin lesions.